Key result
SCN5A-linked Brugada syndrome requires careful risk stratification to prevent sudden cardiac death.
Brugada syndrome remains a challenging clinical entity requiring careful risk stratification and management, primarily with ICDs for high-risk patients.
Demands vigilant SCD prevention in Brugada patients; leaves open refined noninvasive risk stratification tools.
Brugada syndrome (BrS) is a rare congenital arrhythmia syndrome. BrS is characterized by a tendency to syncope, ventricular arrhythmias and sudden cardiac death. These symptoms occur mainly at night and can occur spontaneously or as a result of provocation by, for example, fever, stress or medication. Based on the differences in electrocardiography, three types were distinguished. Genetic studies are being conducted, which have shown a significant defect of the SCN5A gene, which in turn leads to disturbances in the functioning of the sodium channel NaV1.5 has a negative impact on the course of depolarization of myocardial cells. Patients with symptoms of the disease are subjected to implantation of a cardioverter-defibrillator, which protects them against sudden death. Data was obtained from the PubMed and Google Scholar platforms.
No takes yet. Share an insight, caveat, or question.
Misiło et al. (2023) conducted a review in Brugada syndrome. Brugada syndrome is a rare congenital arrhythmia syndrome linked to SCN5A gene defects that requires careful risk stratification and management to prevent sudden cardiac death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: